Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Proceedings of the Modeling Evidence in HPV Pre-Conference Workshop in Malmö, Sweden, May 9-10, 2009.

Craig BM, Brisson M, Chesson H, Giuliano AR, Jit M.

Clin Ther. 2010 Aug;32(8):1546-64. doi: 10.1016/j.clinthera.2010.06.017.

2.

Macromolecular crowding: chemistry and physics meet biology (Ascona, Switzerland, 10-14 June 2012).

Foffi G, Pastore A, Piazza F, Temussi PA.

Phys Biol. 2013 Aug 2;10(4):040301. [Epub ahead of print]

PMID:
23912807
3.

Up to date: comprehensive knowledge of human papillomavirus.

Park JS, Hur S.

Expert Rev Vaccines. 2013 Apr;12(4):353-5. doi: 10.1586/erv.13.8.

PMID:
23560916
4.

Progress in the research on HPV vaccination: updates from the 25th International Papillomavirus Conference in Malmo, Sweden, 2009.

Bonanni P, Boccalini S, Bechini A.

J Prev Med Hyg. 2009 Sep;50(3):131-4. No abstract available.

PMID:
20499474
5.

Rome Consensus Conference - statement; human papilloma virus diseases in males.

Lenzi A, Mirone V, Gentile V, Bartoletti R, Ficarra V, Foresta C, Mariani L, Mazzoli S, Parisi SG, Perino A, Picardo M, Zotti CM.

BMC Public Health. 2013 Feb 7;13:117. doi: 10.1186/1471-2458-13-117.

6.

Implementation of human papillomavirus immunization in the developing world.

Kane MA, Serrano B, de Sanjosé S, Wittet S.

Vaccine. 2012 Nov 20;30 Suppl 5:F192-200. doi: 10.1016/j.vaccine.2012.06.075. Review.

PMID:
23199963
7.

Comparative cost-effectiveness of the quadrivalent and bivalent human papillomavirus vaccines: a transmission-dynamic modeling study.

Brisson M, Laprise JF, Drolet M, Van de Velde N, Franco EL, Kliewer EV, Ogilvie G, Deeks SL, Boily MC.

Vaccine. 2013 Aug 20;31(37):3863-71. doi: 10.1016/j.vaccine.2013.06.064. Epub 2013 Jul 3.

PMID:
23830974
8.

A summary of the 25th International Papillomavirus Conference 2009: vaccines, screening, epidemiology and therapeutics.

Nicol AF, Nuovo GJ, Dillner J.

J Clin Virol. 2010 Mar;47(3):208-15. doi: 10.1016/j.jcv.2009.12.005. Epub 2010 Jan 18.

PMID:
20080439
9.
10.

Economic evaluation of human papillomavirus vaccination in developed countries.

Brisson M, Van de Velde N, Boily MC.

Public Health Genomics. 2009;12(5-6):343-51. doi: 10.1159/000214924. Epub 2009 Aug 11. Review.

PMID:
19684446
11.

Anti-HPV vaccination: a review of recent economic data for Italy.

Mennini FS, Costa S, Favato G, Picardo M.

Vaccine. 2009 May 29;27 Suppl 1:A54-61. doi: 10.1016/j.vaccine.2009.02.052. Review.

PMID:
19480963
12.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; Authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Nov 22;31 Suppl 8:I1-31. doi: 10.1016/j.vaccine.2013.07.026. Review.

13.

Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts.

Wright TC, Bosch FX, Franco EL, Cuzick J, Schiller JT, Garnett GP, Meheus A.

Vaccine. 2006 Aug 31;24 Suppl 3:S3/251-61. Review.

PMID:
16950014
14.

Cost-effectiveness analysis of the bivalent compared with the quadrivalent human papillomavirus vaccines in Taiwan.

Demarteau N, Tang CH, Chen HC, Chen CJ, Van Kriekinge G.

Value Health. 2012 Jul-Aug;15(5):622-31. doi: 10.1016/j.jval.2012.02.012. Epub 2012 Jun 12.

15.

Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia.

Rogovskaya SI, Shabalova IP, Mikheeva IV, Minkina GN, Podzolkova NM, Shipulina OY, Sultanov SN, Kosenko IA, Brotons M, Buttmann N, Dartell M, Arbyn M, Syrjänen S, Poljak M.

Vaccine. 2013 Dec 31;31 Suppl 7:H46-58. doi: 10.1016/j.vaccine.2013.06.043.

PMID:
24332297
16.

Human papillomavirus quadrivalent vaccine: a look behind the numbers.

Flaherty DK, Alkhateeb FM.

Ann Pharmacother. 2009 Apr;43(4):740-4. doi: 10.1345/aph.1L483. Epub 2009 Mar 10. Review.

PMID:
19276314
17.

Comprehensive control of human papillomavirus infections and related diseases.

Bosch FX, Broker TR, Forman D, Moscicki AB, Gillison ML, Doorbar J, Stern PL, Stanley M, Arbyn M, Poljak M, Cuzick J, Castle PE, Schiller JT, Markowitz LE, Fisher WA, Canfell K, Denny LA, Franco EL, Steben M, Kane MA, Schiffman M, Meijer CJ, Sankaranarayanan R, Castellsagué X, Kim JJ, Brotons M, Alemany L, Albero G, Diaz M, de Sanjosé S; authors of the ICO Monograph ‘Comprehensive Control of HPV Infections and Related Diseases’ Vaccine Volume 30, Supplement 5, 2012.

Vaccine. 2013 Dec 29;31 Suppl 5:F1-31. doi: 10.1016/j.vaccine.2013.10.001. Review.

PMID:
24331745
18.
19.

Economic analyses to support decisions about HPV vaccination in low- and middle-income countries: a consensus report and guide for analysts.

Jit M, Levin C, Brisson M, Levin A, Resch S, Berkhof J, Kim J, Hutubessy R.

BMC Med. 2013 Jan 30;11:23. doi: 10.1186/1741-7015-11-23.

20.

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries.

Goldie SJ, O'Shea M, Campos NG, Diaz M, Sweet S, Kim SY.

Vaccine. 2008 Jul 29;26(32):4080-93. doi: 10.1016/j.vaccine.2008.04.053. Epub 2008 May 15.

PMID:
18550229
Items per page

Supplemental Content

Write to the Help Desk